{"protocolSection": {"identificationModule": {"nctId": "NCT01165138", "orgStudyIdInfo": {"id": "106827"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics", "officialTitle": "HZA106827: A Randomised, Double-blind, Placebo-controlled (With Rescue Medication), Parallel Group Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder Alone in the Treatment of Persistent Asthma in Adults and Adolescents"}, "statusModule": {"statusVerifiedDate": "2018-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-08-20"}, "primaryCompletionDateStruct": {"date": "2011-10-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-10-19", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-07-15", "studyFirstSubmitQcDate": "2010-07-15", "studyFirstPostDateStruct": {"date": "2010-07-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-05-30", "resultsFirstSubmitQcDate": "2013-05-30", "resultsFirstPostDateStruct": {"date": "2013-07-30", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2012-05-24", "dispFirstSubmitQcDate": "2012-05-24", "dispFirstPostDateStruct": {"date": "2012-05-31", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-01-18", "lastUpdatePostDateStruct": {"date": "2018-02-14", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder and fluticasone furoate inhalation powder both administered once daily in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 12 week treatment period."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["GW642444", "Vilanterol", "Asthma", "Fluticasone Furoate"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 612, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Fluticasone furoate/Vilanterol (GW642444)", "type": "EXPERIMENTAL", "description": "Fluticasone furoate/Vilanterol inhalation powder once daily for 12 weeks", "interventionNames": ["Drug: Fluticasone furoate/Vilanterol Inhalation Powder"]}, {"label": "Fluticasone Furoate", "type": "EXPERIMENTAL", "description": "Fluticasone furoate inhalation powder once daily for 12 weeks", "interventionNames": ["Drug: Fluticasone Furoate Inhalation Powder"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo inhalation powder once daily for 12 weeks", "interventionNames": ["Drug: Placebo Inhaltion Powder"]}], "interventions": [{"type": "DRUG", "name": "Fluticasone furoate/Vilanterol Inhalation Powder", "description": "Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 12 weeks", "armGroupLabels": ["Fluticasone furoate/Vilanterol (GW642444)"]}, {"type": "DRUG", "name": "Fluticasone Furoate Inhalation Powder", "description": "Fluticasone Furoate Inhalation Powder inhaled orally once daily for 12 weeks", "armGroupLabels": ["Fluticasone Furoate"]}, {"type": "DRUG", "name": "Placebo Inhaltion Powder", "description": "Placebo Inhaltion Powder inhaled orally once daily for 12 weeks", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at Week 12", "description": "Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as the clinic visit (pre-bronchodilator and pre-dose) FEV1measurement taken at the clinic visit while still on-treatment. Pre-dose and pre-rescue albuterol/salbutamol trough FEV1 was measured electronically by spirometry in the evening at the Baseline through Week 12 clinic visits. The highest of 3 technically acceptable measurements was recorded. Baseline was the pre-dose value obtained at Visit 3. Change from Baseline was calculated as the Week 12 value minus the Baseline value. The analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of Baseline trough FEV1, region, sex, age, and treatment group. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing m", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Week 12", "description": "Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at the Baseline and Week 12 clinic visits. Weighted mean was calculated using the 24-hour serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing at Baseline and within 5 minutes prior to dosing at Week 12) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours. At each time point, the highest of 3 technically acceptable measurements was recorded. Baseline was the value obtained at Visit 3. Change from Baseline was calculated as the average Week 12 FEV1 value minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline FEV1, region, sex, age, and treatment group.", "timeFrame": "Baseline and Week 12"}], "secondaryOutcomes": [{"measure": "Mean Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period", "description": "The number of inhalations of rescue albuterol/salbutamol inhalation aerosol used during the day and night was recorded by the participants in a daily electronic diary (eDiary). A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period", "description": "Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in the Total Asthma Quality of Life Questionnaire (AQLQ) (+12) Score at Week 12/Early Withdrawal", "description": "The AQLQ is a disease-specific, self-administered quality of life questionnaire used to evaluate the impact of asthma treatments on the quality of life of asthma sufferers. The AQLQ for 12 years and older (AQLQ \\[+12\\]) is a modified version of the AQLQ for use in asthma patients between the age of 12 and 70. The AQLQ contains 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). For the 32 items on the questionnaire, the response format consists of a seven-point scale, where a value of 1 indicates \"total impairment\" and a value of 7 indicates \"no impairment.\" The AQLQ total score is defined as the average of the scores from all 32 questions; thus, the total score ranges from 1 (indicates \"total impairment\") to 7 (indicates \"no impairment\"). Baseline was the total score obtained at Visit 3. Change from Baseline was calculated as the total score at Week 12 minus the total score at Baseline.", "timeFrame": "Baseline and Week 12/Early Withdrawal"}, {"measure": "Number of Participants Who Withdrew Due to Lack of Efficacy During the 12-week Treatment Period", "description": "The number of participants whose primary reason for withdrawal was lack of efficacy was analyzed.", "timeFrame": "From the first dose of the study medication up to Week 12/Early Withdrawal"}, {"measure": "Serial FEV1 Over 0-1 Hour Post-dose at Randomization", "description": "Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at Randomization. Serial FEV1 measurements after 5, 15, and 30 minutes and 1 hour post-dose were assessed. At each time point, the highest of 3 technically acceptable measurements was recorded. The analysis was performed using a repeated measures model adjusted for baseline, region, sex, age, treatment group, and planned time points.", "timeFrame": "Randomization"}], "otherOutcomes": [{"measure": "Clinic Visit 12-hour Post-dose FEV1 at Week 12", "description": "Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. 12-hour post-dose FEV1 measurements were taken electronically by spirometry at the Week 12 clinic visit. The highest of 3 technically acceptable measurements was recorded. The analysis was performed using an ANCOVA model with covariates of Baseline FEV1, region, sex, age, and treatment group.", "timeFrame": "Week 12"}, {"measure": "Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Baseline", "description": "Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at Baseline. Weighted mean was calculated using the 24-hour serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours. At each time point, the highest of 3 technically acceptable measurements were recorded. Baseline was the value obtained at Visit 3.", "timeFrame": "Baseline"}, {"measure": "Weighted Mean Serial FEV1 Over 0-4 Hours Post-dose at Baseline and Week 12", "description": "Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at the Baseline and Week 12 clinic visits. Weighted mean serial FEV1 over 0-4 hours was calculated using the serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing at Baseline and within 5 minutes prior to dosing at Week 12) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, and 4 hours. At each time point, the highest of 3 technically acceptable measurements were recorded. Baseline was the value obtained at Visit 3.", "timeFrame": "Baseline and Week 12"}, {"measure": "Number of Participants With Bronchodilator Effect", "description": "Bronchodilator effect is defined as an increase of FEV1 (defined as the maximal amount of air that can be forcefully exhaled in one second) from Baseline of both 12% and 200 milliliters (mL) during 24 hours, which was evaluated using the serial FEV1 measurements at Baseline (Visit 3).", "timeFrame": "Baseline"}, {"measure": "Mean Change From Baseline in Daily Morning (AM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period", "description": "Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 12-week treatment period (at Week 12) minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.", "timeFrame": "From Baseline up to Week 12"}, {"measure": "Mean Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period", "description": "PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily PM PEF over the 12-week treatment period (at Week 12) minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.", "timeFrame": "From Baseline up to Week 12"}, {"measure": "Change From Baseline in the Asthma Control Test (ACT) Score at Week 12", "description": "The ACT is a 5-item questionnaire developed as a measure of the participant's asthma control. Questions are designed to be self-completed by the participant and include the following: In the past 4 weeks, \"How much of the time did your asthma keep you from getting as much done at work, school or at home?\", \"How often have you had shortness of breath?\", \"How often did your asthma symptoms wake you up at night or earlier than usual in the morning?\", \"How often have you used your rescue inhaler or nebulizer medication (such as albuterol)?\" and \"How would you rate your asthma control\"? The ACT total score is defined as the sum of the scores from all 5 questions, provided all questions have been answered; thus, the total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma). A score of 20 or higher indicates well-controlled asthma. Change from Baseline was calculated as the total score at Week 12/Early Withdrawal minus the total score at Baseline.", "timeFrame": "Baseline and Week 12/Early Withdrawal"}, {"measure": "Number of Participants With the Indicated Global Assessment of Change Responses at Week 4, Week 8, and Week 12/Early Withdrawal", "description": "At the end of Week 4, Week 8, and Week 12/Early Withdrawal, the Global Assessment of Change Questionnaire that assesses changes in asthma symptoms (AS) and rescue medication use (RMU) was completed by the participants. The number of participants who chose the following answers to the questionnaire were determined: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse (to assess the changes in asthma symptom); much less often , somewhat less often , a little less often , the same , a little more often , somewhat more often , much more often (to assess the changes in the frequency of rescue medication use).", "timeFrame": "Week 4, Week 8, and Week 12/Early Withdrawal"}, {"measure": "Number of the Indicated Unscheduled Asthma-related Healthcare Visits During the Treatment Period", "description": "All unscheduled asthma-related visits to a physician's office, visits to urgent care, visits to the emergency department, and hospitalizations (ICU=intensive care unit; GW=general ward) associated with severe asthma exacerbations or other asthma-related healthcare were recorded.", "timeFrame": "From Baseline up to Week 12/Early Withdrawal"}, {"measure": "Number of Participants Who Used the Inhaler Correctly or Incorrectly at Baseline, Week 2, and Week 4", "description": "Participants were given a demonstration of correct inhaler use (using placebo inhalers), and the participants' competence to correctly use the demonstration inhaler was then assessed.", "timeFrame": "Baseline (BL), Week 2 (W2), and Week 4 (W4)"}, {"measure": "Number of Participants With the Indicated Reason for Incorrect Inhaler Use and Who Required Additional Instruction the Indicated Number of Times at Baseline, Week 2, and Week 4", "description": "Participants were given a demonstration of correct inhaler use (using placebo inhalers), and the participants' competence to correctly use the demonstration inhaler was then assessed based on 3 steps: open the device, inhale the dose, and close the device. If the participants did not perform the maneuvers correctly, the step of the inhaler use that was performed incorrectly by the participants was recorded. The entire procedure was demonstrated once again. and the number of times that the participants required additional instruction (RAI) was recorded.", "timeFrame": "Baseline, Week 2, and Week 4"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Outpatients at least 12 years of age\n* Male and female; female subjects of childbearing potential must be willing to use birth control\n* Pre-bronchodilator FEV1 of 40-90% predicted normal\n* Reversibility FEV1 of at least 12% and 200mL\n* Current asthma therapy includes inhaled corticosteroid use for at least 12 weeks prior to first visit\n\nExclusion Criteria:\n\n* History of life-threatening asthma during last 10 years\n* Respiratory infection or oral candidiasis\n* Asthma exacerbation requiring oral corticosteroids or that required overnight hospitalisation requiring additional asthma treatment\n* Uncontrolled disease or clinical abnormality\n* Allergies to study drugs or the excipients\n* Taking another investigational medication or prohibited medication\n* Night shift workers\n* Current smokers or subjects with a smoking history of at least 10 pack years", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Bell Gardens", "state": "California", "zip": "90201", "country": "United States", "geoPoint": {"lat": 33.96529, "lon": -118.15146}}, {"facility": "GSK Investigational Site", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "GSK Investigational Site", "city": "Long Beach", "state": "California", "zip": "90808", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "GSK Investigational Site", "city": "Los Angeles", "state": "California", "zip": "90048", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "GSK Investigational Site", "city": "Newport Beach", "state": "California", "zip": "92663", "country": "United States", "geoPoint": {"lat": 33.61891, "lon": -117.92895}}, {"facility": "GSK Investigational Site", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "GSK Investigational Site", "city": "Roseville", "state": "California", "zip": "95661", "country": "United States", "geoPoint": {"lat": 38.75212, "lon": -121.28801}}, {"facility": "GSK Investigational Site", "city": "San Diego", "state": "California", "zip": "92120", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "GSK Investigational Site", "city": "Miami", "state": "Florida", "zip": "33173", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "GSK Investigational Site", "city": "Normal", "state": "Illinois", "zip": "61761", "country": "United States", "geoPoint": {"lat": 40.5142, "lon": -88.99063}}, {"facility": "GSK Investigational Site", "city": "River Forest", "state": "Illinois", "zip": "60305", "country": "United States", "geoPoint": {"lat": 41.89781, "lon": -87.81395}}, {"facility": "GSK Investigational Site", "city": "Columbia", "state": "Maryland", "zip": "21044", "country": "United States", "geoPoint": {"lat": 39.24038, "lon": -76.83942}}, {"facility": "GSK Investigational Site", "city": "Rolla", "state": "Missouri", "zip": "65401", "country": "United States", "geoPoint": {"lat": 37.95143, "lon": -91.77127}}, {"facility": "GSK Investigational Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "GSK Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73103", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "GSK Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73112", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "GSK Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "GSK Investigational Site", "city": "Lake Oswego", "state": "Oregon", "zip": "97035", "country": "United States", "geoPoint": {"lat": 45.42067, "lon": -122.67065}}, {"facility": "GSK Investigational Site", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "GSK Investigational Site", "city": "Portland", "state": "Oregon", "zip": "97213", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "GSK Investigational Site", "city": "Orangeburg", "state": "South Carolina", "zip": "29118", "country": "United States", "geoPoint": {"lat": 33.49182, "lon": -80.85565}}, {"facility": "GSK Investigational Site", "city": "Austin", "state": "Texas", "zip": "78756", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "GSK Investigational Site", "city": "Sugar Land", "state": "Texas", "zip": "77479", "country": "United States", "geoPoint": {"lat": 29.61968, "lon": -95.63495}}, {"facility": "GSK Investigational Site", "city": "Murray", "state": "Utah", "zip": "84107", "country": "United States", "geoPoint": {"lat": 40.66689, "lon": -111.88799}}, {"facility": "GSK Investigational Site", "city": "Mannheim", "state": "Baden-Wuerttemberg", "zip": "68161", "country": "Germany", "geoPoint": {"lat": 49.4891, "lon": 8.46694}}, {"facility": "GSK Investigational Site", "city": "Oranienburg", "state": "Brandenburg", "zip": "16515", "country": "Germany", "geoPoint": {"lat": 52.75577, "lon": 13.24197}}, {"facility": "GSK Investigational Site", "city": "Frankfurt am Main", "state": "Hessen", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "GSK Investigational Site", "city": "Gelnhausen", "state": "Hessen", "zip": "63571", "country": "Germany", "geoPoint": {"lat": 50.20164, "lon": 9.18742}}, {"facility": "GSK Investigational Site", "city": "Dresden", "state": "Sachsen", "zip": "01307", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "GSK Investigational Site", "city": "Berlin", "zip": "10787", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Berlin", "zip": "10789", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Berlin", "zip": "12165", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Berlin", "zip": "14057", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Hamburg", "zip": "20354", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "GSK Investigational Site", "city": "Fukuoka", "zip": "811-1394", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "GSK Investigational Site", "city": "Hiroshima", "zip": "732-0052", "country": "Japan", "geoPoint": {"lat": 34.4, "lon": 132.45}}, {"facility": "GSK Investigational Site", "city": "Hokkaido", "zip": "064-0801", "country": "Japan", "geoPoint": {"lat": 43.41104, "lon": 142.88878}}, {"facility": "GSK Investigational Site", "city": "Hyogo", "zip": "672-8048", "country": "Japan"}, {"facility": "GSK Investigational Site", "city": "Ishikawa", "zip": "920-8530", "country": "Japan", "geoPoint": {"lat": 26.42333, "lon": 127.82139}}, {"facility": "GSK Investigational Site", "city": "Kagawa", "zip": "762-0031", "country": "Japan"}, {"facility": "GSK Investigational Site", "city": "Kanagawa", "zip": "252-0143", "country": "Japan", "geoPoint": {"lat": 37.58333, "lon": 139.91667}}, {"facility": "GSK Investigational Site", "city": "Kyoto", "zip": "603-8161", "country": "Japan", "geoPoint": {"lat": 35.02107, "lon": 135.75385}}, {"facility": "GSK Investigational Site", "city": "Okinawa", "zip": "901-2132", "country": "Japan", "geoPoint": {"lat": 26.33583, "lon": 127.80139}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "158-0083", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "171-0014", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "194-0023", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tarnow", "zip": "33-100", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"facility": "GSK Investigational Site", "city": "Tczew", "zip": "83-110", "country": "Poland", "geoPoint": {"lat": 54.09242, "lon": 18.77787}}, {"facility": "GSK Investigational Site", "city": "Wroclaw", "zip": "53-301", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "GSK Investigational Site", "city": "Zawadzkie", "zip": "47-120", "country": "Poland", "geoPoint": {"lat": 50.60503, "lon": 18.48467}}, {"facility": "GSK Investigational Site", "city": "Bucharest", "zip": "020674", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "GSK Investigational Site", "city": "Cluj Napoca", "zip": "400371", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "GSK Investigational Site", "city": "Craiova", "zip": "200642", "country": "Romania", "geoPoint": {"lat": 44.31667, "lon": 23.8}}, {"facility": "GSK Investigational Site", "city": "Deva", "zip": "330084", "country": "Romania", "geoPoint": {"lat": 45.88333, "lon": 22.9}}, {"facility": "GSK Investigational Site", "city": "Pitesti", "zip": "110084", "country": "Romania", "geoPoint": {"lat": 44.85, "lon": 24.86667}}, {"facility": "GSK Investigational Site", "city": "Ploiesti", "zip": "100550", "country": "Romania", "geoPoint": {"lat": 44.95, "lon": 26.01667}}, {"facility": "GSK Investigational Site", "city": "Suceava", "zip": "720284", "country": "Romania", "geoPoint": {"lat": 47.63333, "lon": 26.25}}, {"facility": "GSK Investigational Site", "city": "Timisoara", "zip": "300310", "country": "Romania", "geoPoint": {"lat": 45.75372, "lon": 21.22571}}, {"facility": "GSK Investigational Site", "city": "Dnipropetrovsk", "zip": "49006", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "GSK Investigational Site", "city": "Dnipropetrovsk", "zip": "49051", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "GSK Investigational Site", "city": "Ivano-Frankivsk", "zip": "76018", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "GSK Investigational Site", "city": "Kharkiv", "zip": "61035", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "GSK Investigational Site", "city": "Kiev", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "02091", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "02660", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "03038", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "03115", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "04201", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Simferopol", "zip": "95043", "country": "Ukraine", "geoPoint": {"lat": 44.95719, "lon": 34.11079}}, {"facility": "GSK Investigational Site", "city": "Zaporizhia", "zip": "69076", "country": "Ukraine", "geoPoint": {"lat": 47.82289, "lon": 35.19031}}]}, "referencesModule": {"references": [{"pmid": "27881132", "type": "DERIVED", "citation": "O'Byrne PM, Jacques L, Goldfrad C, Kwon N, Perrio M, Yates LJ, Busse WW. Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Respir Res. 2016 Nov 24;17(1):157. doi: 10.1186/s12931-016-0473-x."}, {"pmid": "26704701", "type": "DERIVED", "citation": "Gross AS, Goldfrad C, Hozawa S, James MH, Clifton CS, Sugiyama Y, Jacques L. Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials. BMC Pulm Med. 2015 Dec 24;15:165. doi: 10.1186/s12890-015-0159-z."}, {"pmid": "25213048", "type": "DERIVED", "citation": "Bleecker ER, Lotvall J, O'Byrne PM, Woodcock A, Busse WW, Kerwin EM, Forth R, Medley HV, Nunn C, Jacques L, Bateman ED. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. J Allergy Clin Immunol Pract. 2014 Sep-Oct;2(5):553-61. doi: 10.1016/j.jaip.2014.02.010. Epub 2014 Apr 24."}, {"pmid": "24966061", "type": "DERIVED", "citation": "Svedsater H, Jacques L, Goldfrad C, Bleecker ER. Ease of use of the ELLIPTA dry powder inhaler: data from three randomised controlled trials in patients with asthma. NPJ Prim Care Respir Med. 2014 Jun 26;24:14019. doi: 10.1038/npjpcrm.2014.19. No abstract available."}, {"pmid": "24314123", "type": "DERIVED", "citation": "Svedsater H, Dale P, Garrill K, Walker R, Woepse MW. Qualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013 Dec 7;13:72. doi: 10.1186/1471-2466-13-72."}], "seeAlsoLinks": [{"label": "Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.", "url": "https://www.clinicalstudydatarequest.com"}], "availIpds": [{"id": "106827", "type": "Annotated Case Report Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106827", "type": "Statistical Analysis Plan", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106827", "type": "Informed Consent Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106827", "type": "Individual Participant Data Set", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106827", "type": "Clinical Study Report", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106827", "type": "Study Protocol", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106827", "type": "Dataset Specification", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants meeting eligibility criteria at the Screening visit completed a 4-week Run-in Period for Baseline safety evaluations and measures of asthma status. Participants were then randomized to a 12-week Treatment Period. 1110 participants were screened, 610 were randomized, and 609 received \\>=1 dose of study treatment.", "groups": [{"id": "FG000", "title": "Current Anti-asthma Therapy at a Fixed Dose", "description": "Participants were instructed to continue using an approved fixed dose of an inhaled corticosteroid (ICS) for 4 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Run-in Period."}, {"id": "FG001", "title": "Placebo", "description": "Participants (par.) received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "FG002", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "FG003", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "203"}, {"groupId": "FG002", "numSubjects": "205"}, {"groupId": "FG003", "numSubjects": "201"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "151"}, {"groupId": "FG002", "numSubjects": "185"}, {"groupId": "FG003", "numSubjects": "179"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "52"}, {"groupId": "FG002", "numSubjects": "20"}, {"groupId": "FG003", "numSubjects": "22"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "32"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "BG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "BG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "203"}, {"groupId": "BG001", "value": "205"}, {"groupId": "BG002", "value": "201"}, {"groupId": "BG003", "value": "609"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "38.1", "spread": "16.49"}, {"groupId": "BG001", "value": "40.4", "spread": "16.78"}, {"groupId": "BG002", "value": "40.7", "spread": "16.38"}, {"groupId": "BG003", "value": "39.7", "spread": "16.56"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "111"}, {"groupId": "BG001", "value": "126"}, {"groupId": "BG002", "value": "116"}, {"groupId": "BG003", "value": "353"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "92"}, {"groupId": "BG001", "value": "79"}, {"groupId": "BG002", "value": "85"}, {"groupId": "BG003", "value": "256"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "African American/African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "13"}, {"groupId": "BG003", "value": "43"}]}]}, {"title": "American Indian or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "Asian - Japanese Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "50"}]}]}, {"title": "Asian - South East Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "White - Arabic/North African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "White - White/Caucasian/European Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "169"}, {"groupId": "BG001", "value": "170"}, {"groupId": "BG002", "value": "172"}, {"groupId": "BG003", "value": "511"}]}]}, {"title": "Mixed Race", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at Week 12", "description": "Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as the clinic visit (pre-bronchodilator and pre-dose) FEV1measurement taken at the clinic visit while still on-treatment. Pre-dose and pre-rescue albuterol/salbutamol trough FEV1 was measured electronically by spirometry in the evening at the Baseline through Week 12 clinic visits. The highest of 3 technically acceptable measurements was recorded. Baseline was the pre-dose value obtained at Visit 3. Change from Baseline was calculated as the Week 12 value minus the Baseline value. The analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of Baseline trough FEV1, region, sex, age, and treatment group. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing m", "populationDescription": "Intent-to-Treat (ITT) Population: all participants randomized to treatment, who received at least one dose of the study medication. Only those participants with non-missing covariates and post-Baseline FEV1 data were analyzed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "203"}, {"groupId": "OG002", "value": "200"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.196", "spread": "0.0310"}, {"groupId": "OG001", "value": "0.332", "spread": "0.0302"}, {"groupId": "OG002", "value": "0.368", "spread": "0.0304"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "statisticalMethod": "ANCOVA", "paramType": "Median Difference (Final Values)", "paramValue": "0.136", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.051", "ciUpperLimit": "0.222"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Median Difference (Final Values)", "paramValue": "0.172", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.087", "ciUpperLimit": "0.258"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.405", "statisticalMethod": "ANCOVA", "paramType": "Median Difference (Final Values)", "paramValue": "0.036", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.048", "ciUpperLimit": "0.120"}]}, {"type": "PRIMARY", "title": "Change From Baseline in Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Week 12", "description": "Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at the Baseline and Week 12 clinic visits. Weighted mean was calculated using the 24-hour serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing at Baseline and within 5 minutes prior to dosing at Week 12) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours. At each time point, the highest of 3 technically acceptable measurements was recorded. Baseline was the value obtained at Visit 3. Change from Baseline was calculated as the average Week 12 FEV1 value minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline FEV1, region, sex, age, and treatment group.", "populationDescription": "ITT Population. Weighted mean serial FEV1 was calculated for the subset of participants for whom serial FEV1 was performed at Week 12.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "106"}, {"groupId": "OG002", "value": "108"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.212", "spread": "0.0456"}, {"groupId": "OG001", "value": "0.398", "spread": "0.0432"}, {"groupId": "OG002", "value": "0.513", "spread": "0.0430"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.003", "statisticalMethod": "ANCOVA", "paramType": "Median Difference (Final Values)", "paramValue": "0.186", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.062", "ciUpperLimit": "0.310"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Median Difference (Final Values)", "paramValue": "0.302", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.178", "ciUpperLimit": "0.426"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.060", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.116", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.005", "ciUpperLimit": "0.236"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period", "description": "The number of inhalations of rescue albuterol/salbutamol inhalation aerosol used during the day and night was recorded by the participants in a daily electronic diary (eDiary). A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of rescue-free 24-hr periods", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "204"}, {"groupId": "OG002", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "17.8", "spread": "2.26"}, {"groupId": "OG001", "value": "26.5", "spread": "2.25"}, {"groupId": "OG002", "value": "37.1", "spread": "2.26"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period", "description": "Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of symptom-free 24-hr periods", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "204"}, {"groupId": "OG002", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14.6", "spread": "2.15"}, {"groupId": "OG001", "value": "20.4", "spread": "2.13"}, {"groupId": "OG002", "value": "32.5", "spread": "2.14"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Total Asthma Quality of Life Questionnaire (AQLQ) (+12) Score at Week 12/Early Withdrawal", "description": "The AQLQ is a disease-specific, self-administered quality of life questionnaire used to evaluate the impact of asthma treatments on the quality of life of asthma sufferers. The AQLQ for 12 years and older (AQLQ \\[+12\\]) is a modified version of the AQLQ for use in asthma patients between the age of 12 and 70. The AQLQ contains 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). For the 32 items on the questionnaire, the response format consists of a seven-point scale, where a value of 1 indicates \"total impairment\" and a value of 7 indicates \"no impairment.\" The AQLQ total score is defined as the average of the scores from all 32 questions; thus, the total score ranges from 1 (indicates \"total impairment\") to 7 (indicates \"no impairment\"). Baseline was the total score obtained at Visit 3. Change from Baseline was calculated as the total score at Week 12 minus the total score at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline and Week 12/Early Withdrawal", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "184"}, {"groupId": "OG002", "value": "180"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.61", "spread": "0.061"}, {"groupId": "OG001", "value": "0.76", "spread": "0.055"}, {"groupId": "OG002", "value": "0.91", "spread": "0.055"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Who Withdrew Due to Lack of Efficacy During the 12-week Treatment Period", "description": "The number of participants whose primary reason for withdrawal was lack of efficacy was analyzed.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "From the first dose of the study medication up to Week 12/Early Withdrawal", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "203"}, {"groupId": "OG001", "value": "205"}, {"groupId": "OG002", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "7"}]}]}]}, {"type": "SECONDARY", "title": "Serial FEV1 Over 0-1 Hour Post-dose at Randomization", "description": "Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at Randomization. Serial FEV1 measurements after 5, 15, and 30 minutes and 1 hour post-dose were assessed. At each time point, the highest of 3 technically acceptable measurements was recorded. The analysis was performed using a repeated measures model adjusted for baseline, region, sex, age, treatment group, and planned time points.", "populationDescription": "ITT Population. Serial FEV1 was calculated for the subset of participants for whom serial FEV1 was performed. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Randomization", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "203"}, {"groupId": "OG001", "value": "205"}, {"groupId": "OG002", "value": "201"}]}], "classes": [{"title": "5 Minutes, n=117, 112, 117", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.489", "spread": "0.0308"}, {"groupId": "OG001", "value": "2.493", "spread": "0.0314"}, {"groupId": "OG002", "value": "2.484", "spread": "0.0308"}]}]}, {"title": "15 Minutes, n=118, 115, 117", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.491", "spread": "0.0336"}, {"groupId": "OG001", "value": "2.529", "spread": "0.0342"}, {"groupId": "OG002", "value": "2.566", "spread": "0.0336"}]}]}, {"title": "30 Minutes, n=118, 116, 118", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.532", "spread": "0.0354"}, {"groupId": "OG001", "value": "2.552", "spread": "0.0359"}, {"groupId": "OG002", "value": "2.596", "spread": "0.0354"}]}]}, {"title": "1 Hour, n=119, 116, 119", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.552", "spread": "0.0344"}, {"groupId": "OG001", "value": "2.571", "spread": "0.0350"}, {"groupId": "OG002", "value": "2.674", "spread": "0.0344"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Clinic Visit 12-hour Post-dose FEV1 at Week 12", "description": "Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. 12-hour post-dose FEV1 measurements were taken electronically by spirometry at the Week 12 clinic visit. The highest of 3 technically acceptable measurements was recorded. The analysis was performed using an ANCOVA model with covariates of Baseline FEV1, region, sex, age, and treatment group.", "populationDescription": "ITT Population. 12-hour post-dose FEV1 was analyzed in the subset of participants for whom serial FEV1 at Week 12 was performed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "93"}, {"groupId": "OG001", "value": "104"}, {"groupId": "OG002", "value": "108"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.462", "spread": "0.0502"}, {"groupId": "OG001", "value": "2.674", "spread": "0.0475"}, {"groupId": "OG002", "value": "2.830", "spread": "0.0468"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Baseline", "description": "Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at Baseline. Weighted mean was calculated using the 24-hour serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours. At each time point, the highest of 3 technically acceptable measurements were recorded. Baseline was the value obtained at Visit 3.", "populationDescription": "ITT Population. Weighted mean serial FEV1 was calculated in the subset of participants for whom serial FEV1 was performed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "119"}, {"groupId": "OG001", "value": "116"}, {"groupId": "OG002", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.543", "spread": "0.8494"}, {"groupId": "OG001", "value": "2.552", "spread": "0.7527"}, {"groupId": "OG002", "value": "2.709", "spread": "0.8153"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Weighted Mean Serial FEV1 Over 0-4 Hours Post-dose at Baseline and Week 12", "description": "Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at the Baseline and Week 12 clinic visits. Weighted mean serial FEV1 over 0-4 hours was calculated using the serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing at Baseline and within 5 minutes prior to dosing at Week 12) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, and 4 hours. At each time point, the highest of 3 technically acceptable measurements were recorded. Baseline was the value obtained at Visit 3.", "populationDescription": "ITT Population. Weighted mean serial FEV1 was calculated in the subset of participants for whom serial FEV1 at Week 12 was performed. Only those participants available at the specified time points were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "119"}]}], "classes": [{"title": "Baseline, n=120, 115, 119", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.563", "spread": "0.8194"}, {"groupId": "OG001", "value": "2.522", "spread": "0.7479"}, {"groupId": "OG002", "value": "2.693", "spread": "0.7626"}]}]}, {"title": "Week 12, n=96, 105, 109", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.636", "spread": "0.8519"}, {"groupId": "OG001", "value": "2.657", "spread": "0.7912"}, {"groupId": "OG002", "value": "2.894", "spread": "0.8383"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Participants With Bronchodilator Effect", "description": "Bronchodilator effect is defined as an increase of FEV1 (defined as the maximal amount of air that can be forcefully exhaled in one second) from Baseline of both 12% and 200 milliliters (mL) during 24 hours, which was evaluated using the serial FEV1 measurements at Baseline (Visit 3).", "populationDescription": "ITT Population. Only the subset of participants performing serial measurements were analyzed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "116"}, {"groupId": "OG002", "value": "120"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "73", "lowerLimit": "0", "upperLimit": "272.0"}, {"groupId": "OG001", "value": "77", "lowerLimit": "0", "upperLimit": "270.0"}, {"groupId": "OG002", "value": "97", "lowerLimit": "0", "upperLimit": "62.0"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Mean Change From Baseline in Daily Morning (AM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period", "description": "Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 12-week treatment period (at Week 12) minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters per minute", "timeFrame": "From Baseline up to Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "204"}, {"groupId": "OG002", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "2.42"}, {"groupId": "OG001", "value": "18.3", "spread": "2.41"}, {"groupId": "OG002", "value": "32.9", "spread": "2.42"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Mean Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period", "description": "PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily PM PEF over the 12-week treatment period (at Week 12) minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters per minute", "timeFrame": "From Baseline up to Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "204"}, {"groupId": "OG002", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "spread": "2.36"}, {"groupId": "OG001", "value": "14.1", "spread": "2.34"}, {"groupId": "OG002", "value": "26.4", "spread": "2.35"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in the Asthma Control Test (ACT) Score at Week 12", "description": "The ACT is a 5-item questionnaire developed as a measure of the participant's asthma control. Questions are designed to be self-completed by the participant and include the following: In the past 4 weeks, \"How much of the time did your asthma keep you from getting as much done at work, school or at home?\", \"How often have you had shortness of breath?\", \"How often did your asthma symptoms wake you up at night or earlier than usual in the morning?\", \"How often have you used your rescue inhaler or nebulizer medication (such as albuterol)?\" and \"How would you rate your asthma control\"? The ACT total score is defined as the sum of the scores from all 5 questions, provided all questions have been answered; thus, the total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma). A score of 20 or higher indicates well-controlled asthma. Change from Baseline was calculated as the total score at Week 12/Early Withdrawal minus the total score at Baseline.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline and Week 12/Early Withdrawal", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "189"}, {"groupId": "OG002", "value": "185"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.5", "spread": "0.26"}, {"groupId": "OG001", "value": "3.8", "spread": "0.23"}, {"groupId": "OG002", "value": "4.4", "spread": "0.23"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Participants With the Indicated Global Assessment of Change Responses at Week 4, Week 8, and Week 12/Early Withdrawal", "description": "At the end of Week 4, Week 8, and Week 12/Early Withdrawal, the Global Assessment of Change Questionnaire that assesses changes in asthma symptoms (AS) and rescue medication use (RMU) was completed by the participants. The number of participants who chose the following answers to the questionnaire were determined: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse (to assess the changes in asthma symptom); much less often , somewhat less often , a little less often , the same , a little more often , somewhat more often , much more often (to assess the changes in the frequency of rescue medication use).", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 4, Week 8, and Week 12/Early Withdrawal", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "174"}, {"groupId": "OG001", "value": "198"}, {"groupId": "OG002", "value": "191"}]}], "classes": [{"title": "Week 4, AS - Much better, n=174, 198, 191", "categories": [{"measurements": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "47"}, {"groupId": "OG002", "value": "65"}]}]}, {"title": "Week 4, AS - Somewhat better, n=174, 198, 191", "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "61"}]}]}, {"title": "Week 4, AS - A little better, n=174, 198, 191", "categories": [{"measurements": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "47"}, {"groupId": "OG002", "value": "37"}]}]}, {"title": "Week 4, AS - The same, n=174, 198, 191", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "29"}, {"groupId": "OG002", "value": "23"}]}]}, {"title": "Week 4, AS - A little worse, n=174, 198, 191", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Week 4, AS - Somewhat worse, n=174, 198, 191", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Week 4, AS - Much worse, n=174, 198, 191", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Week 4, RMU - Much less often, n=174, 198, 191", "categories": [{"measurements": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "75"}]}]}, {"title": "Week 4, RMU - Somewhat less often, n=174, 198, 191", "categories": [{"measurements": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "48"}, {"groupId": "OG002", "value": "51"}]}]}, {"title": "Week 4, RMU - A little less often, n=174, 198, 191", "categories": [{"measurements": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "32"}]}]}, {"title": "Week 4, RMU - The same, n=174, 198, 191", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "33"}, {"groupId": "OG002", "value": "28"}]}]}, {"title": "Week 4, RMU - A little more often, n=174, 198, 191", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Week 4, RMU - Somewhat more often, n=174, 198, 191", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Week 4, RMU - Much more often, n=174, 198, 191", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Week 8, AS - Much better, n=159, 192, 184", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "69"}]}]}, {"title": "Week 8, AS - Somewhat better, n=159, 192, 184", "categories": [{"measurements": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "63"}]}]}, {"title": "Week 8, AS - A little better, n=159, 192, 184", "categories": [{"measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "40"}, {"groupId": "OG002", "value": "22"}]}]}, {"title": "Week 8, AS - The same, n=159, 192, 184", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "33"}, {"groupId": "OG002", "value": "24"}]}]}, {"title": "Week 8, AS - A little worse, n=159, 192, 184", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Week 8, AS - Somewhat worse, n=159, 192, 184", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Week 8, AS - Much worse, n=159, 192, 184", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Week 8, RMU - Much less often, n=159, 191, 184", "categories": [{"measurements": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "86"}]}]}, {"title": "Week 8, RMU - Somewhat less often, n=159, 191, 184", "categories": [{"measurements": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "48"}, {"groupId": "OG002", "value": "43"}]}]}, {"title": "Week 8, RMU - A little less often, n=159, 191, 184", "categories": [{"measurements": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "34"}, {"groupId": "OG002", "value": "25"}]}]}, {"title": "Week 8, RMU - The same, n=159, 191, 184", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "39"}, {"groupId": "OG002", "value": "23"}]}]}, {"title": "Week 8, RMU - A little more often, n=159, 191, 184", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "Week 8, RMU - Somewhat more often, n=159, 191, 184", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Week 8, RMU - Much more often, n=159, 191, 184", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Week 12, AS - Much better, n=152, 187, 182", "categories": [{"measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "66"}, {"groupId": "OG002", "value": "86"}]}]}, {"title": "Week 12, AS - Somewhat better, n=152, 187, 182", "categories": [{"measurements": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "52"}]}]}, {"title": "Week 12, AS - A little better, n=152, 187, 182", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "13"}]}]}, {"title": "Week 12, AS - The same, n=152, 187, 182", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "23"}]}]}, {"title": "Week 12, AS - A little worse, n=152, 187, 182", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "7"}]}]}, {"title": "Week 12, AS - Somewhat worse, n=152, 187, 182", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Week 12, AS - Much worse, n=152, 187, 182", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Week 12, RMU - Much less often, n=150, 187, 182", "categories": [{"measurements": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "76"}, {"groupId": "OG002", "value": "89"}]}]}, {"title": "Week 12, RMU -Somewhat less often, n=150, 187, 182", "categories": [{"measurements": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "46"}, {"groupId": "OG002", "value": "43"}]}]}, {"title": "Week 12, RMU -A little less often, n=150, 187, 182", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "21"}]}]}, {"title": "Week 12, RMU - The same, n=150, 187, 182", "categories": [{"measurements": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "32"}, {"groupId": "OG002", "value": "23"}]}]}, {"title": "Week 12, RMU -A little more often, n=150, 187, 182", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "Week 12, RMU -Somewhat more often, n=150, 187, 182", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Week 12, RMU - Much more often, n=150, 187, 182", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of the Indicated Unscheduled Asthma-related Healthcare Visits During the Treatment Period", "description": "All unscheduled asthma-related visits to a physician's office, visits to urgent care, visits to the emergency department, and hospitalizations (ICU=intensive care unit; GW=general ward) associated with severe asthma exacerbations or other asthma-related healthcare were recorded.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Number of visits", "timeFrame": "From Baseline up to Week 12/Early Withdrawal", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "203"}, {"groupId": "OG001", "value": "205"}, {"groupId": "OG002", "value": "201"}]}], "classes": [{"title": "Number of Home Visits (Day)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "0.00"}, {"groupId": "OG001", "value": "0.0", "spread": "0.00"}, {"groupId": "OG002", "value": "0.0", "spread": "0.00"}]}]}, {"title": "Number of Home Visits (Night)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "0.00"}, {"groupId": "OG001", "value": "0.0", "spread": "0.00"}, {"groupId": "OG002", "value": "0.0", "spread": "0.00"}]}]}, {"title": "Number of Physician Office/Practice Visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "0.24"}, {"groupId": "OG001", "value": "0.0", "spread": "0.39"}, {"groupId": "OG002", "value": "0.0", "spread": "0.10"}]}]}, {"title": "Number of Urgent Care/Outpatient Clinic Visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "0.07"}, {"groupId": "OG001", "value": "0.0", "spread": "0.07"}, {"groupId": "OG002", "value": "0.0", "spread": "0.00"}]}]}, {"title": "Number of Emergency Room Visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "0.00"}, {"groupId": "OG001", "value": "0.0", "spread": "0.00"}, {"groupId": "OG002", "value": "0.0", "spread": "0.00"}]}]}, {"title": "Number of Inpatient Hospitalization Days (ICU)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "0.00"}, {"groupId": "OG001", "value": "0.0", "spread": "0.00"}, {"groupId": "OG002", "value": "0.0", "spread": "0.00"}]}]}, {"title": "Number of Inpatient Hospitalization (GW) Days", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "0.00"}, {"groupId": "OG001", "value": "0.0", "spread": "0.00"}, {"groupId": "OG002", "value": "0.0", "spread": "0.00"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Participants Who Used the Inhaler Correctly or Incorrectly at Baseline, Week 2, and Week 4", "description": "Participants were given a demonstration of correct inhaler use (using placebo inhalers), and the participants' competence to correctly use the demonstration inhaler was then assessed.", "populationDescription": "ITT Population. Only those participants available at the specified time points were analyzed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline (BL), Week 2 (W2), and Week 4 (W4)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "203"}, {"groupId": "OG001", "value": "205"}, {"groupId": "OG002", "value": "201"}]}], "classes": [{"title": "BL: Used Inhaler Correctly, n=203, 205, 201", "categories": [{"measurements": [{"groupId": "OG000", "value": "194"}, {"groupId": "OG001", "value": "196"}, {"groupId": "OG002", "value": "188"}]}]}, {"title": "BL: Used Inhaler Incorrectly, n=203, 205, 201", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "13"}]}]}, {"title": "W2: Used Inhaler Correctly, n=190, 203, 200", "categories": [{"measurements": [{"groupId": "OG000", "value": "190"}, {"groupId": "OG001", "value": "203"}, {"groupId": "OG002", "value": "200"}]}]}, {"title": "W2: Used Inhaler Incorrectly, n=190, 203, 200", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "W4: Used Inhaler Correctly, n=175, 199, 195", "categories": [{"measurements": [{"groupId": "OG000", "value": "175"}, {"groupId": "OG001", "value": "199"}, {"groupId": "OG002", "value": "195"}]}]}, {"title": "W4: Used Inhaler Incorrectly, n=175, 199, 195", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Participants With the Indicated Reason for Incorrect Inhaler Use and Who Required Additional Instruction the Indicated Number of Times at Baseline, Week 2, and Week 4", "description": "Participants were given a demonstration of correct inhaler use (using placebo inhalers), and the participants' competence to correctly use the demonstration inhaler was then assessed based on 3 steps: open the device, inhale the dose, and close the device. If the participants did not perform the maneuvers correctly, the step of the inhaler use that was performed incorrectly by the participants was recorded. The entire procedure was demonstrated once again. and the number of times that the participants required additional instruction (RAI) was recorded.", "populationDescription": "ITT Population. Only those participants who used the inhaler incorrectly at the specified time points were analyzed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, Week 2, and Week 4", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}, {"id": "OG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "13"}]}], "classes": [{"title": "BL: Opened the Device Incorrectly, n= 9, 9, 13", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "BL: Inhaled the Dose Incorrectly, n= 9, 9, 13", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "BL: Closed the Device Incorrectly, n= 9, 9, 13", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "BL: RAI once, n= 9, 9, 13", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "8"}]}]}, {"title": "BL: RAI 2 Times, n= 9, 9, 13", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "BL: RAI 3 Times, n= 9, 9, 13", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "BL: RAI >3 Times, n= 9, 9, 13", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "W2: Opened the Device Incorrectly, n= 0, 0, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no data can be reported at this time point."}, {"groupId": "OG001", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no data can be reported at this time point."}, {"groupId": "OG002", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no data can be reported at this time point."}]}]}, {"title": "W2: Inhaled the Dose Incorrectly, n= 0, 0, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no data can be reported at this time point."}, {"groupId": "OG001", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no data can be reported at this time point."}, {"groupId": "OG002", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no data can be reported at this time point."}]}]}, {"title": "W2: Closed the Device Incorrectly, n= 0, 0, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no data can be reported at this time point."}, {"groupId": "OG001", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no data can be reported at this time point."}, {"groupId": "OG002", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no data can be reported at this time point."}]}]}, {"title": "W2: RAI once, n= 0, 0, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no participants required additional instruction."}, {"groupId": "OG001", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no participants required additional instruction."}, {"groupId": "OG002", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no participants required additional instruction."}]}]}, {"title": "W2: RAI 2 Times, n= 0, 0, 0,", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no participants required additional instruction."}, {"groupId": "OG001", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no participants required additional instruction."}, {"groupId": "OG002", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no participants required additional instruction."}]}]}, {"title": "W2: RAI 3 Times, n= 0, 0, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no participants required additional instruction."}, {"groupId": "OG001", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no participants required additional instruction."}, {"groupId": "OG002", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 2; thus, no participants required additional instruction."}]}]}, {"title": "W4: Opened the Device Incorrectly, n= 0, 0, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no data can be reported at this time point."}, {"groupId": "OG001", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no data can be reported at this time point."}, {"groupId": "OG002", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no data can be reported at this time point."}]}]}, {"title": "W4: Inhaled the Dose Incorrectly, n= 0, 0, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no data can be reported at this time point."}, {"groupId": "OG001", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no data can be reported at this time point."}, {"groupId": "OG002", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no data can be reported at this time point."}]}]}, {"title": "W4: Closed the Device Incorrectly, n= 0, 0, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no data can be reported at this time point."}, {"groupId": "OG001", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no data can be reported at this time point."}, {"groupId": "OG002", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no data can be reported at this time point."}]}]}, {"title": "W4: RAI once, n= 0, 0, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no participants required additional instruction."}, {"groupId": "OG001", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no participants required additional instruction."}, {"groupId": "OG002", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no participants required additional instruction."}]}]}, {"title": "W4: RAI 2 Times, n= 0, 0, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no participants required additional instruction."}, {"groupId": "OG001", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no participants required additional instruction."}, {"groupId": "OG002", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no participants required additional instruction."}]}]}, {"title": "W4: RAI 3 Times, n= 0, 0, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no participants required additional instruction."}, {"groupId": "OG001", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no participants required additional instruction."}, {"groupId": "OG002", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no participants required additional instruction."}]}]}, {"title": "W4: RAI >3 Times, n= 0, 0, 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no participants required additional instruction."}, {"groupId": "OG001", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no participants required additional instruction."}, {"groupId": "OG002", "value": "NA", "comment": "No participants used the inhaler incorrectly at Week 4; thus, no participants required additional instruction."}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "Serious Adverse Events (SAEs) and non-serious AEs were collected from the first dose of study medication up to Week 12/Early Withdrawal.", "description": "SAEs and AEs were collected in members of Intent-to-Treat (ITT) Population, comprised of all participants randomized to treatment, who received at least one dose of the study medication.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period.", "seriousNumAffected": 0, "seriousNumAtRisk": 203, "otherNumAffected": 22, "otherNumAtRisk": 203}, {"id": "EG001", "title": "FF 100 \u00b5g OD", "description": "Participants received Fluticasone Furoate (FF) 100 microgram (\u00b5g) inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period.", "seriousNumAffected": 1, "seriousNumAtRisk": 205, "otherNumAffected": 20, "otherNumAtRisk": 205}, {"id": "EG002", "title": "FF/VI 100/25 \u00b5g OD", "description": "Participants received FF/Vilanterol (VI) 100/25 \u00b5g inhalation powder OD in the evening from the DPI for 12 weeks. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period.", "seriousNumAffected": 0, "seriousNumAtRisk": 201, "otherNumAffected": 29, "otherNumAtRisk": 201}], "seriousEvents": [{"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 203}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 205}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 201}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 203}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 205}, {"groupId": "EG002", "numAffected": 20, "numAtRisk": 201}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 203}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 205}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 201}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Clinic visit", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}